header logo image


Page 305«..1020..304305306307..310320..»

Vaccines and Approved Antibodies Could Dim Vir Biotechnologys Covid Opportunity – Barron’s

December 10th, 2020 4:55 am

Text size

The tiny Vir Biotechnology was vaulted from obscurity this year, when it said it was developing treatments for Covid-19. Its stock (ticker: VIR) shot from $12 to a March peak of $75, before settling back to the mid-30swhere GlaxoSmithKline (GSK) bought a $250 million stake.

Vir started clinical trials in August for its antibody treatment against Covid-19. But the train has left the station, says Baird analyst Madhu Kumar, and Vir may have missed its Covid business opportunity. Antibodies from Eli Lilly (LLY) and Regeneron Pharmaceutical (REGN) have already gotten emergency use authorizations from regulators and booked orders. Demand for any Covid-19 treatment will start to shrink with the imminent authorization of vaccines from Pfizer (PFE), BioNTech (BNTX) and Moderna (MRNA).

In a Thursday note, Kumar reiterated his Underperform rating for Vir stock, whose shares he thinks should fall to $24 from their recent level near $32.

The Baird analyst went to a sell rating after Virs initial jump in February, and has maintained steady criticism since, in nearly 40 notes. Vir could find success with another treatment it is testing against hepatitis B, says Kumar, but future sales of such a product would only be worth $14 in current value. Ascribing $3.50 in value for Virs other pipeline programs, and counting its $6.50 a share in cash, brings Kumar to his $24 fair value.

Antibodies from Regeneron were among the treatments given to President Donald Trump in October, when he got Covid.

Newsletter Sign-up

Every weekday evening we highlight the consequential market news of the day and explain what's likely to matter tomorrow.

Virs securities filings say that its Covid-19 antibody trial could produce interim results in January 2021, and a final readout later in that years first quarter. The Baird analyst doesnt expect an authorization and product launch until the springby which point vaccines should be getting into wide supply.

Meanwhile, the bridging opportunity for anti-Covid antibodies is being snapped up by Lilly and Regeneron. The U.S. government arranged to buy 950,000 doses of Lillys treatment, including a deal for 650,000 doses announced Wednesday that will bring $850 million to Lilly.

Write to Bill Alpert at william.alpert@barrons.com

View original post here:
Vaccines and Approved Antibodies Could Dim Vir Biotechnologys Covid Opportunity - Barron's

Read More...

Department Of Biotechnology’s Expert Committee Tracking Developments Related To COVID-19 Vaccine: Official | News – Swachh India NDTV

December 10th, 2020 4:55 am

Maharashtra

DistrictCases

Mumbai45,478

Thane13,660

Pune9,920

Mumbai Suburban5,363

Aurangabad1,974

Nashik1,575

Raigad1,462

Palghar1,421

Solapur1,291

Jalgaon1,039

Akola757

Nagpur692

Kolhapur646

Satara629

Ratnagiri350

Amravati291

Dhule228

Hingoli208

Jalna201

Ahmednagar190

Nanded176

Yavatmal150

Sangli145

Latur139

Osmanabad125

Sindhudurg114

Buldhana88

Parbhani78

gondia69

Beed54

Nandurbar42

Gadchiroli42

Bhandara41

Chandrapur32

Washim13

Wardha11

18,64,348 4,981

74,315 145

17,42,131 5,051

47,902 75

DistrictCases

Udupi1,176

Kalaburagi669

Yadgir538

Bengaluru Urban529

Raichur369

Mandya346

Belagavi337

Bidar219

Hassan205

Davangere204

Vijayapura201

Dakshina Kannada179

Chikkaballapura149

Mysuru107

Bagalkote103

Uttara Kannada95

Shivamogga67

Dharwad61

Ballari60

Gadag45

Bengaluru Rural40

Tumakuru36

Kolar29

Haveri24

Chikkamagaluru19

Chitradurga14

Koppal5

Kodagu4

Ramanagara3

Chamarajanagara0

8,96,563 1,279

23,075 1,959

8,61,588 3,218

11,900 20

DistrictCases

Kurnool795

Krishna557

Guntur511

Anantapur428

East Godavari356

Chittoor319

Sri Potti Sriramulu Nell*296

Y.S.R.205

West Godavari199

Srikakulam183

Prakasam104

Visakhapatnam103

Vizianagaram23

8,73,457 618

5,259 170

8,61,153 785

7,045 3

DistrictCases

Chennai23,324

Chengalpattu1,314

Thiruvallur774

Villupuram509

View original post here:
Department Of Biotechnology's Expert Committee Tracking Developments Related To COVID-19 Vaccine: Official | News - Swachh India NDTV

Read More...

Analyst Rating: Will PDS Biotechnology Corp (PDSB) Stock Outperform the Market? – InvestorsObserver

December 10th, 2020 4:55 am

Analysts who follow PDS Biotechnology Corp (PDSB) on average expect it to increase 209.68% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy.

That average rating earns PDSB an Analyst Ranking of 79, which means it ranks higher than 79 of stocks, based on data compiled by InvestorsObserver.

Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve.

InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.

PDS Biotechnology Corp (PDSB) stock is trading at $2.17 as of 1:08 PM on Wednesday, Dec 9, a loss of -$0.26, or -10.7% from the previous closing price of $2.43. The stock has traded between $2.15 and $2.40 so far today. Volume today is 585,089 compared to average volume of 614,574.

Click Here to get the full report on PDS Biotechnology Corp (PDSB) Stock.

Continued here:
Analyst Rating: Will PDS Biotechnology Corp (PDSB) Stock Outperform the Market? - InvestorsObserver

Read More...

Where Does Crispr Therapeutics AG (CRSP) Stock Fall in the Biotechnology Field? – InvestorsObserver

December 10th, 2020 4:55 am

A rating of 80 puts Crispr Therapeutics AG (CRSP) near the top of the Biotechnology industry according to InvestorsObserver. Crispr Therapeutics AG's score of 80 means it scores higher than 80% of stocks in the industry. Crispr Therapeutics AG also received an overall rating of 64, putting it above 64% of all stocks. Biotechnology is ranked 36 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 64 means the stock is more attractive than 64 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Crispr Therapeutics AG (CRSP) stock is higher by 4.47% while the S&P 500 has fallen -0.3% as of 1:19 PM on Monday, Dec 7. CRSP is higher by $6.60 from the previous closing price of $147.54 on volume of 2,324,656 shares. Over the past year the S&P 500 has gained 17.61% while CRSP is higher by 128.52%. CRSP lost -$3.25 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.

See the rest here:
Where Does Crispr Therapeutics AG (CRSP) Stock Fall in the Biotechnology Field? - InvestorsObserver

Read More...

Tuskegee University College of Veterinary Medicine treats social media famous patient Brisket the Bull – Tuskegee University

December 8th, 2020 8:00 pm

December 04, 2020

Contact: Anissa Riley, College of Veterinary Medicine

Tuskegee University College of Veterinary Medicine students recently had the opportunity to assist veterinary large animal clinicians and surgeons in the medical treatment of a social media famous patient who goes by the name, Brisket the Bull. Brisket was given a clean bill of health on December 1 from the veterinary medical teaching hospital and then released to his owner.

The eight-year old Brahman bull is owned by Judy Presley, formerly from Tennessee but now a resident of Luverne, Alabama. Presley bought Brisket at a sale barn when he was just two years old. Over the years, she has raised and trained him to accept a halter, saddle and to be ridden. Brisket has a very gentle temperament and is nationally recognized for his owner's ability to trail ride and show jump with him.

Brisket had a two-month history of an abscessed prepuce in which the abscess was treated by a private practice before being brought to the veterinary hospital for a sheath resection, which was a surgery successfully performed by Dr. Jeannine Bellamy, veterinary medical teaching hospital director, and myself providing the anesthesia, said Dr. David McKenzie, professor and large animal clinician in the Large Animal Clinical Sciences Department.

The students assisted in the medical aftercare in which Briskets healing progressed well and led to a recent successful discharge. Briskets owner Judy was very pleased with the services of the college in treating Brisket and offered to have the students take pictures with him and be shared on Briskets Facebook and fan social media pages.

We are proud of our students and thankful to our large animal veterinary medical clinicians for providing quality healthcare for our bovine clients. Being exceptional is what we are striving to be here at Tuskegee and have our clients be pleased with the veterinary services provided to our patients while preparing our students to be career-ready veterinarians upon completing the veterinary curriculum, said Dr. Ruby L. Perry, dean of the College of Veterinary Medicine.

To learn more about the College and the Tuskegee Veterinary Medical Teaching Hospital, visit http://www.tuskegee.edu/vetmed and http://www.tuskegee.edu/vetcare.

2020 Tuskegee University

See the article here:
Tuskegee University College of Veterinary Medicine treats social media famous patient Brisket the Bull - Tuskegee University

Read More...

Medicine expert joins faculty of Texas Tech School of Veterinary Medicine – KLBK | KAMC | EverythingLubbock.com

December 8th, 2020 8:00 pm

AMARILLO and LUBBOCK, Texas (NEWS RELEASE) The following is a news release from Texas Tech University:

Say the words New York and most people will think of the large, metropolitan area that is the financial and shopping center of the U.S. Few, if any, say agriculture.

Yet if you get outside of the main city, the state of New York is an important contributor of agricultural products in the country. The state has a $3.6 billion agricultural industry with more than 35,000 farms producing products from apples and cabbage to milk and cheese, grapes, maple syrup and cauliflower.

It is here where Emily Sundman was raised and saw firsthand the critical role agriculture has on the state and the importance of those who care for farm animals. This became the foundation for a career supporting animal health.

That career now brings her to West Texas as the latest member to join the faculty of the newTexas Tech School of Veterinary Medicine in Amarilloas an assistant professor of medicine. She began her duties on Tuesday (Dec. 1).

I am thrilled to join the Texas Tech School of Veterinary Medicine in time to welcome the inaugural class, Sundman said. Working at the School of Veterinary Medicine is a career dream realized in order to further veterinary care for our large animals.

Sundman has spent much of her career involved in agricultural industry research and development, inventing ways to directly and positively impact animal health and assisting practicing veterinarians who seek to do the same.

Since December 2013, Sundman has served a role in clinical development for Kindred Biosciences, which takes strategies that are safely used for human therapeutics and applies them to the development of animal biologics, such as monoclonal antibodies and recombinant proteins.

From 2013 to 2017, she oversaw the clinical development phase, including efficacy and safety, of new animal pharmaceuticals for approval by the United States Department of Agriculture (USDA), the Food and Drug Administration (FDA) and the Committee for Medicinal Products for Veterinary Use (CVMP). She also designed and executed clinical studies and was primarily responsible for pharmaceuticals for use in horses, dogs and cats.

She was promoted to Senior Clinical Development Manager in 2017, where she was responsible for the approval of Zimeta IV for use in controlling fever in horses in the U.S. She served in this role until September, when she was promoted to Associate Director of Clinical Development, increasing the responsibilities for early phase strategy and development of products for USDA and CVMP approval.

Sundman also has been co-owner and veterinarian at Picolino Ranch since 2015. The ranch, located in Lipan, Texas, specializes in the breeding and development of Aberdeen cattle, raising them to become accustomed to the pastureland and climate associated with North Texas. Since 2013, she has served as an emergency equine ambulatory veterinarian serving in Davis, California, and later the Lipan areas.

2020 has shown us the importance of innovation, saidGuy Loneragan, dean of the School of Veterinary Medicine. To help with and prevent COVID-19, the call went out for new therapies and for new vaccines. Innovative products are now arriving, and society has benefited from this research and discovery. Veterinary medicine is no different. Our animals large and small benefit from new therapies and new preventatives. Dr. Sundman will add to our schools vibrant research and discovery efforts. She also serves an important role helping our researchers design the best possible trials to test new discoveries. We are so lucky Dr. Sundman has joined our school. We will benefit so very much from what she contributes.

Sundman earned bachelors degrees in history and biology from Syracuse University and her Doctor of Veterinary Medicine from Cornell University in 2012. At Cornell, she was influenced greatly working by professor and veterinarian Lisa Fortier. Thats where Sundman said she got a good look at what true veterinary research was like.

Sundman has been a Diplomat of the American Board of Veterinary Practitioners (Equine Practice) since 2019.

Dr. Sundman brings a unique background to our program from industry and research, which will help guide our faculty in their programs, saidJohn Dascanio, senior associate dean for academic and student affairs. Combining that experience with her clinical background allows for application toward clinical practice, enabling her to serve as a great mentor to the school and to the faculty. We welcome her to her new role with the school.

Sundman joins a growing and vibrant team of faculty and staff at the School of Veterinary Medicine. Additional team members will continue to be added over the next few months as the school prepares to welcome its inaugural class in the fall of 2021.

Thanks to the generosity of Amarillo and communities across Texas, and the commitment of legislators from around the state, the Texas Tech University School of Veterinary Medicine in Amarillo was established in 2018. In September 2020, the school was granted a Letter of Reasonable Assurance, from the American Veterinary Medical Association (AVMA) Council on Education and has begun the admissions process in preparation for classes to begin in August of 2021.

The School of Veterinary Medicine will recruit and select students with a passion to serve rural and regional communities. Its curriculum is focused on the competencies and skills necessary for success in practice types that support these communities. Texas Techs innovative and cost-efficient model partners with the wider community of veterinary practices across the state to provide clinical, real-world experiential learning.

(News release from Texas Tech University)

See the rest here:
Medicine expert joins faculty of Texas Tech School of Veterinary Medicine - KLBK | KAMC | EverythingLubbock.com

Read More...

What to know about cherry eye in dogs – New Castle News

December 8th, 2020 8:00 pm

Spotting a red bump in the corner of a pets eye is a concerning but not uncommon experience for many dog owners. Colloquially called cherry eye, this bump may be a prolapsed gland of the nictitans, also known as the third eyelid.

Dr. Sean Collins, a clinical assistant professor at the Texas A&M College of Veterinary Medicine & Biomedical Sciences, says that ophthalmologists dont entirely understand why the gland of the nictating membrane sometimes protrudes from its original position but it is believed to be a result of a weakness in the connective tissue responsible for holding the gland in the correct position.

This condition can happen to any breed of dog but is seen most commonly in certain breeds, including the American cocker spaniel, English bulldog, Lhasa apso, and the Pekingese, Collins said.

Pet owners who spot a red swollen mass in the inner corner of their pets eye, large or small, should bring it to their veterinarians attention promptly. In addition to causing irritation to the dog, this condition can have lasting consequences when left untreated.

Without correction, chronic prolapse can lead to conjunctivitis (pink eye) and ocular discharge (liquid coming from the eye), Collins said. It has also been shown that with correction, dogs are less likely to develop low tear production later in life.

Low tear production can result in multiple problems if left untreated. In addition to pain and decreased vision, corneal ulceration may also develop, which can become infected and result in a ruptured eye. This condition responds well to tear stimulant therapy in most cases, but lifelong medication is usually required.

Story continues below video

Your veterinarian will be able to confirm whether your pet has cherry eye and can develop a treatment plan that works best to resolve cherry eye and reduce the potential for ocular issues as your dog ages.

Initial therapy may consist of topical anti-inflammatory therapy if local inflammation may be contributing to prolapse of the gland, he said. If a short course of medical therapy does not work or re-prolapse develops, surgical repositioning is indicated. There are numerous surgical techniques to reposition the gland with overall high success rates.

If surgical treatment is required, Collins stresses that this treatment will benefit your pet in both the short- and long-term.

Surgical repositioning is very important if initial medical therapy fails, as the gland is responsible for about 30-50% of the aqueous tear production in the dog, he said. We commonly see low tear production in the same breeds that develop a prolapsed gland of the nictitans. It has been shown that dogs with surgical repositioning of the gland have a lower chance of developing low tear production later on in life compared to those where the gland has been excised or remains chronically prolapsed.

Unfortunately, there are no known preventative measures to protect against cherry eye in dogs, Collins says. This condition can develop in both eyes, usually before the age of 2. The best way pet owners can protect their furry friend is to remain vigilant in monitoring their pets health and to bring concerns to their veterinarian promptly in case an issue does arise.

Pet Talk is a service of the College of Veterinary Medicine & Biomedical Sciences, Texas A&M University. Stories can be viewed on the web at vetmed.tamu.edu/news/pet-talk. Suggestions for future topics may be directed to editor@cvm.tamu.edu.

More here:
What to know about cherry eye in dogs - New Castle News

Read More...

Veterinarians at OSU develop vaccine technology that could protect against COVID-19 and measles at the same time – 10TV

December 8th, 2020 8:00 pm

Two veterinarians from OSU's College of Veterinary Medicine took a measles vaccine and added the COVID-19 spike protein as a response to the global pandemic.

COLUMBUS, Ohio Ohio doctors are working to develop vaccine technology to protect us from COVID-19.

Dr. Jianrong Liand Dr. Stefan Niewiesk from Ohio State University's College of Veterinary Medicine took a measles vaccine and added the COVID-19 spike protein as a response to the global pandemic.

The resultwas a vaccine that is shown to protect against both measles and COVID-19 in at least animals.

The next step is testing humans.

The vaccine could be particularly helpful in developing countries, as it does not require the same refrigeration as the mRNA vaccines.

"We think the measles virus is a very good vaccine because it has a long-standing safety record. It has been instrumental in reducing the measles virus worldwide," Niewiesk said. "We think that given all the data it makes a very effective vaccine. Also, given the fact, it protects life-long against measles virus infections so ideally (and we do not know this yet) it would also protect for a very long time against COVID-19."

Biological E. Limited and the Ohio State Innovation Foundation announced an exclusive license agreement on Tuesday for the vaccine technology.

The company will be responsible for the evaluation and further development, including the commercialization of the vaccine candidate(s).

Translating this vaccine platform into the hands of a global vaccine company for further evaluation and development is a critical step and we are excited that Biological E has taken on this role, said Dr. Patrick Green, Associate Dean for Research and Graduate Studies, Ohio State University College of Veterinary Medicine.

Mahima Datla, Managing Director of Biological. E. Limited added, "BE has been working to develop a safe and effective vaccine for the COVID-19. BE is very happy to help further this innovation and expand that effort."

To read more about the technology, click here.

Originally posted here:
Veterinarians at OSU develop vaccine technology that could protect against COVID-19 and measles at the same time - 10TV

Read More...

USDA Awards Grant To Texas A&M To Develop AI-Based Wildlife Monitoring – Texas A&M University Today

December 8th, 2020 8:00 pm

Purple martins on one of the new nesting box systems.

Doug Bonham, Field Data Technologies

A research team led by the Texas A&M University College of Veterinary Medicine & Biomedical Sciences (CVMBS) has been awarded a nearly $700,000 Conservation Innovation Grant from the U.S. Department of Agriculture (USDA) to develop a new artificial intelligence-based wildlife monitoring system.

The Conservation Innovation Grant program, under the USDA Natural Resources Conservation Service, supports the development of new tools, approaches, practices and technologies to further natural resource conservation on private lands.

The grant will be used by principal investigator and CVMBS associate professor Dr. Donald Brightsmith and his team to integrate camera, image and sensor data to create a tool to monitor wildlife that are typically difficult to observe, including pollinators, reptiles, amphibians and nesting birds.

Currently, landowners do not have many options for measuring their wildlife conservation efforts, such as setting up nesting boxes for birds or preserving areas of natural land, besides bringing in teams of scientists for hand surveys, a costly and lengthy process. Since private land makes up so much of the U.S., landowners efforts play a key role in the countrys overall wildlife management and conservation.

Brightsmiths team, in conjunction with colleagues from the University of California, Santa Barbara, the University of Hawaii and private industry, is working to develop a low-cost and easy-to-use system that will allow producers to monitor wildlife on their land and understand how their actions directly affect the local environment.

Part of our grant is to make it so a typical landowner can easily use a laptop or phone app to see the information that came in from a specific camera, such as where that camera is on a map; the weather, temperature, light, and humidity there; and the critters that were at that camera, Brightsmith said.

Commercial wildlife cameras already allow landowners to monitor wildlife on a small scale, but by using artificial intelligence to aggregate and analyze data from a number of cameras and locations, landowners will be able to see a much more complete picture.

The camera system will photograph the scene and, whenever there is a significant change, forward images to a central computer that will use artificial intelligence to identify species, behaviors and trends. According to Connie Woodman, a member of Brightsmiths team and graduate student in the CVMBS Department of Veterinary Pathobiology (VTPB,) this process would traditionally take scientists dozens of hours to conduct surveys and sort through photos.

Baby chickadees inside a nesting box.

Doug Bonham, Field Data Technologies

If this sort of technology could be available at low cost or free to farmers, it could really impact the ability to see if conserving farmland and private land is working, Woodman said. Its just too expensive to have a hands-on survey for every property owner who wants to apply for government support to maintain wild lands and wildlife populations.

The camera system will be used in three different setups a ground setup to monitor reptiles and amphibians, a veil trap setup for insects and a bird nesting box setup. In all three uses, the animals photographed will be free from any harm or human interference.

One of the other objectives within this is if landowners are doing land management activities like cutting, spraying, or planting, they will be able to look at the data coming in to immediately see how those changes in the ecosystem have impacted key reptiles, amphibians, birds and bees, Brightsmith said.

An early version of the nest box setup has already been deployed in the Pacific Northwest by collaborators within Field Data Technologies and is providing invaluable data on chickadee and purple martin nesting behaviors.

Its doing more than just taking photos; its spitting out data. How many eggs? When was there a change? How many times is the nest being visited? How many times does a chickadee investigate a nest box before it decides that its good enough? Woodman said. With that data we can tell a land manager, The chickadee started visiting the nest boxes X weeks before it used them. So if you wait until June to hang up the box, you wont get any use this year.'

While the grant will directly support the technologys creation and use in supporting landowners, Brightsmith hopes that the technology will one day also be adapted to create systems that could survey for invasive species and agricultural pests, monitor wildlife recovery after natural disasters, and more.

If we build a technology thats fairly straightforward to train the AI, someone else can take our platform and tweak it, he said. Our objective is to create a system that has unlimited potential.

The system will initially be tested in Arizona, California, Texas and Montana to see how it works in different environments. The team has already partnered with producers and other landowners near Austin, San Antonio and southern California to see how the technology holds up around large animals like cattle.

Along with Brightsmith and Woodman, collaborators on this grant include Drs. Chris Evelyn and Katja Seltmann, from the University of California, Santa Barbara, Cheadle Center for Biodiversity and Ecological Restoration; Dr. Ethel Villalobos, from the University of Hawaii at Manoa; and Doug Bonham, senior electronics engineer at Microsoft and the founder and president of Field Data Technologies of Essex, Montana.

Read more here:
USDA Awards Grant To Texas A&M To Develop AI-Based Wildlife Monitoring - Texas A&M University Today

Read More...

Research resuming on campuses – American Veterinary Medical Association

December 8th, 2020 8:00 pm

Chris Cramer, PhD, said in early November the University of Minnesota had reached about 80% of its research output prior to the pandemic.

Dr. Cramer is vice president for research and leader of a research group in the Department of Chemistry. He said the university is keeping lower numbers of people in laboratories and other research sites as well as restricting work involving human participants in uncontrolled environments, such as grade schools.

Otherwise, weve been pretty successful in bringing back most of the stuff that would require someone to come to campus, go to a field site, whatever it might be, he said.

Early this year, university research leaders described how their institutions delayed the start of new research, reduced staffing in research facilities, and added safety measures to ongoing studies.

By late spring, universities were publishing and implementing phased plans for resuming research, each with their own plans on how to protect investigators, participants, and the public.

Texas A&M Universitys Division of Research, for example, published in June plans for how investigators could resume research involving human participants and other clinical studies, as well as published overall research plans including an update as the fall semester began.

Johns Hopkins University officials published their JHU Return to Research Guidance on June 12, with limits on the time and activities allowed on campus, reduced capacity in laboratories, and added responsibilities for reducing transmission risks. The guidance states that some projects may proceed at a slower pace, and some studies may be lower priorities.

Isaac Pessah, PhD, associate dean and professor of molecular biosciences at the University of California-Davis School of Veterinary Medicine, said the university had been ramping up research after a substantial reduction early in the pandemic. The university maintained studies deemed essential, continued breeding irreplaceable animal lines, and maintained other animal populations while pausing new studies unrelated to COVID-19.

Starting June 1, UC-Davis officials allowed up to 33% of research personnel on-site for time-sensitive studies, with distancing and personal protective equipment requirements. Starting Oct. 30, the allowances expanded to all studies that need on-site access.

The next phase, whenever that may come, would allow two-thirds of research personnel on-site, resumption of field research, and expansion of all research activities.

Dr. Douglas K. Taylor is senior veterinarian in the Emory University School of Medicine Division of Animal Resources and a professor of pathology and laboratory medicine. He said in late October that Emorys research-use mouse populationthe bulk of the institutions research animal populationwas down about 15% from early March, when it was at an all-time high. The volume of research at the institution also was down about 15%.

We are certainly not back where we were in the beginning of the year, he said.

Dr. Joyce Cohen, associate director of animal resources at the Yerkes National Primate Research Center and associate professor in the Emory University School of Medicine Division of Psychiatry and Behavioral Sciences, said the primate research facility, in contrast, remained insanely busy.

We never really slowed down much during COVID, she said. We stopped doing new projects, but we didnt stop any ongoing projects with nonhuman primates.

Dr. Cohen said that, as the pause on new projects ended, more investigators started studies amid a torrent of ongoing research. The primate research center closed the fiscal year with more than $88 million in grant income, a record high.

Were having problems because of monkey shortages, she said.

In a typical year, Yerkes officials would be able to supplement their rhesus macaque population by buying more. But pharmaceutical companies are competing for all domestic sources of rhesus macaques because importation channels closed during the pandemic.

The Atlantic reported Aug. 31 that China provided 60% of the 35,000 monkeys imported to the U.S. in 2019 but halted those exports early this year.

Dr. Cohen said the center expanded its breeding colony, but each macaque can give birth only each spring, following a six-month gestation period. They become viable for research at 3 years old and optimal for studies at 5.

Dr. Taylor said the physical distancing rules at Emoryand most research institutions he knows oflimit the number of researchers in a procedure room. Dr. Cohen said all of Yerkes animal resource staff had returned with staggered shifts, and researchers have adjusted with unusual schedules to reduce laboratory occupancy.

We still have constraints with PPE, she said. Its still challenging. Weve been OK. Weve been able to get things, but its never a guarantee that well have enough face shields or enough masks.

Dr. Cramer said the pandemic also continues to hinder research among people whose work depends on travel, such as investigators in the humanities, social sciences, and geology. The university removed a previous restriction on domestic travel but continues to restrict international travel.

Veterinary researchers, in particular, struggled this year with deciding how to continue clinical trials involving pets and how they should protect pet owners, Dr. Cramer said. A Missouri resident might own a dog with cancer and travel to Minnesota to participate in a clinical trial, he said.

Should we have them do that, given the challenges associated with it for the individual? he said. And then, of course, how do you protect your staff and people in the veterinary clinic?

By early November, the volume of clinical trials in the veterinary clinic almost met the volume from before the pandemic, in part because travel is less uncertain, Dr. Cramer said.

In the spring, researchers and spokespeople at several universities indicated in interviews with JAVMA News they had reduced breeding of research animals, and a few depopulated mice in efforts to reduce the risks to human health. One institution sent livestock used in teaching laboratories to market earlier than planned.

Some news reports published at that time gave the impression research institutions were implementing widespread euthanasia of research rodents. Dr. Cohen said that, while some institutions euthanized research animals early in the pandemic, she thinks that was rare and institutions more often paused rodent breeding during the uncertain early months.

Dr. Pessah said research scientists across the UC-Davis campus, including the veterinary school, wonder whether the campus administration had been responsive to concerns about delays in studies unrelated to COVID-19.

But we are also very cognizant of safety as we move forward to ramp up, he said. So there are mitigating programs that have been put in place, especially for more junior faculty thatif your research has been delayed to the point where it has an impact on your ability to fulfill the missions in your grantsyou can apply for bridge funding to try to mitigate those delays.

The Office of Research leads that effort in cooperation with the deans, Dr. Pessah said. The amount available will depend on demand.

Most of the studies out of the School of Veterinary Medicine, though, met the definition of essential research because they deal with topics such as food animal health and food safety or require ongoing data collection to avoid massive losses, Dr. Pessah said.

Weve had a very open line of communication with all researcherswhether they use animals, cell lines, or a combinationto make sure that their essential research continues and their safety is maintained, he said.

As theoreticians, Dr. Cramer and the members of his research group work from home, in doing so following an order from Gov. Tim Walz that all people can work from home when possible. For other teams, the most challenging aspect tended to be deciding how to schedule workspace in ways that give people appropriate distance from one another while considering the space usually needed for their work.

When the fall semester began, though, new researchers needed training on laboratory techniques.

Sometimes, you need to be standing side by side with somebody, Dr. Cramer said. So, weve had to think about what things should be delayed in terms of training new people. Can we come up with techniques to deliver training without requiring folks to be too close to one another for too long a period?

For now, some of the trainers have relied on video-based training, whereas in-person instructors simply stood further away during their lessons and added plexiglass barriers, he said.

Though some researchers at the University of Minnesota developed COVID-19, none of those infections were traced to their workplaces or co-workers, Dr. Cramer said.

As for the research animal population, the University of Minnesotas mouse population was about 80% of its pre-pandemic total and climbing, Dr. Cramer said. Activity in the vivariums remained down to provide distance between researchers.

Dr. Taylor said that, for research institutions, business was returning to normal. He said researchers at Emory remained dedicated to their work and know it is important.

The work goes on, he said. The animals need to be taken care of. The research needs to move forward.

Read more from the original source:
Research resuming on campuses - American Veterinary Medical Association

Read More...

Study: Bartonella Infection Associated With Psychiatric Symptoms and Skin Lesions – NC State News

December 8th, 2020 8:00 pm

Bartonella bacteria are increasingly recognized as an emerging infectious disease threat. A new study by North Carolina State University researchers has found additional instances of Bartonella infection in humans who exhibited neuropsychiatric symptoms, a subset of whom also had skin lesions. This research adds to the body of evidence that not only can Bartonella infection mimic a spectrum of chronic illnesses including mental illness but also that dermatological symptoms may accompany infection.

Bartonella henselae is a bacterium historically associated with cat-scratch disease, which until recently was thought to be a short-lived (or self-limiting) infection. There are at least 30 different known Bartonella species, of which 13 have been found to infect humans. Improved methods for detecting Bartonella infection in animals and humans it is notorious for hiding in the linings of blood vessels and potentially the skin has led to the diagnosis of bartonelloses in patients with a host of chronic illnesses.

In 2019, Dr. Edward Breitschwerdt, Melanie S. Steele Distinguished Professor of Internal Medicine at NCState, published a case study involving an adolescent boy diagnosed with rapid onset schizophrenia, who had accompanying skin lesions. After Breitschwerdts research group documented Bartonella henselae infection, the patient received antimicrobial therapy and all neuropsychiatric symptoms resolved.

The new study is a follow-up to the 2019 work and is published in the journal Pathogens. Thirty-three participants suffering from neuropsychiatric symptoms ranging from sleep disorders and migraines to depression and anxiety enrolled in the study. Twenty-nine of 33 participants were found to have Bartonella infections based upon serology and enrichment blood culture polymerase chain reaction (PCR) testing. Twenty-four of the 29 Bartonella-positive participants (83%) reported the appearance of skin lesions during their illness.

Skin lesions ranged from cutaneous eruptions to red, irregular linear lesions randomly located on various parts of the patients body. Many of these lesions resembled striae distensae (stretch marks); however, typical risk factors for striae distensae, such as body building activities, obesity, pregnancy, prednisone treatment and other known disease associations, were either infrequently or not reported by study participants.

This research, a follow-up to our initial case report of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS), was initiated to further investigate a possible association between neuropsychiatric illness, skin lesions and a bacterial infection of emerging biomedical importance, Breitschwerdt says. We hope that this research will enable physicians to suspect connections between disparate symptoms involving the nervous system and skin that could be associated with an underlying bacterial cause.

Breitschwerdt is the first and corresponding author of the research, which was supported by the Bartonella/Vector-Borne Diseases Research Fund at NCStates College of Veterinary Medicine. NCState research technician Julie Bradley, postdoctoral researcher Erin Lashnits, and research professor Ricardo Maggi, as well as dermatologist Paul Reicherter of the University of Missouri Kansas City Truman Medical Center, contributed to the work.

-peake-

Note to editors: An abstract follows.

Bartonella Associated Cutaneous Lesions (BACL) in People with Neuropsychiatric Symptoms

DOI: 10.3390/pathogens9121023

Authors: Ed Breitschwerdt, Julie Bradley, Ricardo Maggi, Erin Lashnits, North Carolina State University; Paul Reicherter, University of Missouri Kansas CityPublished: Online Dec. 7, 2020 in Pathogens

Abstract:Bartonella species are globally important emerging pathogens that were not known to infect animals or humans in North America prior to the human immunodeficiency virus (HIV) epidemic. Ongoing improvements in diagnostic testing modalities have allowed for the discovery of Bartonella species (spp.) DNA in blood; cerebrospinal fluid; and the skin of patients with cutaneous lesions, fatigue, myalgia, and neurological symptoms. We describe Bartonella spp. test results for participants reporting neuropsychiatric symptoms, the majority of whom reported the concurrent development of cutaneous lesions. Study participants completed a medical history, a risk factor questionnaire, and provided cutaneous lesion photographs. Bartonella spp. serology and Bartonella alpha proteobacteria enrichment blood culture/PCR were assessed. Within a 14-month period, 33 participants enrolled; 29/33 had serological and/or PCR evidence supporting Bartonella spp. infection, of whom 24 reported concurrent cutaneous lesions since neuropsychiatric symptom onset. We conclude that cutaneous lesions were common among people reporting neuropsychiatric symptoms and Bartonella spp. infection or exposure. Additional studies, using sensitive microbiological and imaging techniques, are needed to determine if, or to what extent, Bartonella spp. might contribute to cutaneous lesions and neuropsychiatric symptoms in patients.

See more here:
Study: Bartonella Infection Associated With Psychiatric Symptoms and Skin Lesions - NC State News

Read More...

New research marketing campaign part of CSU progress report to Board of Governors – Source

December 8th, 2020 8:00 pm

CSU System CFO Henry Sobanet provided an update on Gov. Jared Polis budget request including a $494 million general fund increase to public higher education to restore operating support for colleges and universities to the $825 million funding level of fiscal year 2020. If approved, the CSU System would receive $101.6 million. The governors request also allows up to a 3% increase in resident, undergraduate tuition rates.

Budget Each spring, typically in May, the Board finalizes the budget for the coming year. During the bimonthly meetings leading up to budget approval, the Board receives financial updates which model multiple scenarios reflecting updated projections of factors such as enrollment trends and the anticipated funding for higher education from the legislature.

The Board reviewed models for the Education and General Budget which assume state funding at the level of fiscal year 2020, a slightly greater than typical enrollment decline from fall to spring, and tuition increases of 0% or 3%. Given ongoing financial challenges, including those from COVID-19, the CSU models project a fiscal shortfall in the range of $19.7 million to $28.6 million. Consistent with the Governors budget request, there are no salary increases included in the current CSU budget modeling for FY2021. The Board continues to implement its multi-year strategy of managing the shortfall created by COVID-19. At the February meeting the Board will further discuss how to resolve a shortfall if those revenue projections hold steady after updates to enrollment figures and new state revenue projections.

Faculty Representative Report Professor Stephanie Clemons discussed CSUs nation-leading sustainability ranking and the successful in-person fall semester. Clemons is retiring, and Faculty Council will designate a new representative who will fill the role starting at the Boards February meeting.

Student Representative Report ASCSU President Hannah Taylor shared priorities that Associated Students of CSU are focusing on including: a petition drive for a ballot initiative to change the citys You+2 policy to ME+3; health initiatives including mass ordering of thermometers for students, mental health support, flu shot promotion; and support for Rams Against Hunger. Taylor also discussed ASCSUs mentor program for academics and a partnership with Rocky Mountain Student Media to do monthly fireside chats shared online on the CTV YouTube channel.

See the article here:
New research marketing campaign part of CSU progress report to Board of Governors - Source

Read More...

How to talk to pet owners about preventive care – Jill Lopez

December 8th, 2020 8:00 pm

Disease prevention is integral to practicing high-quality veterinary medicine. We aim to maintain pet health, yet we are often faced with sick animals whose owners were unaware of the importance of ongoingpreventive and wellness care. We need to focus on educating clients about the importance of disease prevention at every wellness appointment, but especially with new clients and at new pet appointments.

Improving Health and Quality of Life

Keeping pets happy and healthy is the ultimate goal of the veterinarian and pet owners partnership. Talk to the owner about how preventive care improves their pets longevity and quality of life. Consistently remind owners that preventive wellness checks are essential to meeting this goal. Communicate that unremarkable wellness exams are a sign of success, not wasted time or money.

Emphasize to clients that proactive disease screening is an important part of preventive care. Early diagnosis can simplify the treatment of many types of diseases, reducing costs and the long-term morbidity of many diseases. Overall, early intervention improves prognosis and the patients quality of life.

Preventive Care Benefits

Another important point of discussion is that disease prevention saves money. Even simple health issues can quickly become expensive if treatment has been delayed or postponed. Meanwhile, more serious health issues and emergencies are often a major financial burden to many clients. With wellness care, we can avoid some of these emergencies.

Reducing Zoonotic Risks

Furthermore, good preventive care that includes parasite control and vaccinations such as rabies and leptospirosis can reduce the incidence of zoonosis, avoiding the associated health impacts and healthcare costs.

Using Examples To Support the Benefits

Choosing an example to contrast the consequences of the disease with the simplicity of prevention or early intervention is a powerful way to educate the client on the benefits of preventive care. Some good examples include parvovirus, heartworm disease, leptospirosis, chronic kidney disease, or tumors.Picking ones that are most relevant to the individual patient create the most impact in the discussion.

If we can emphatically communicate the importance of disease prevention, we can see many more patients for regular wellness visits. This will provide us with better business, happy clients, and improved pet health.

Read more from the original source:
How to talk to pet owners about preventive care - Jill Lopez

Read More...

PET TALK: Seeing the signs: What to know about cherry eye in dogs – Houston Chronicle

December 8th, 2020 8:00 pm

Spotting a red bump in the corner of a pets eye is a concerning but not uncommon experience for many dog owners. Colloquially called cherry eye, this bump may be a prolapsed gland of the nictitans, also known as the third eyelid.

Dr. Sean Collins, a clinical assistant professor at the Texas A&M College of Veterinary Medicine, says that ophthalmologists dont entirely understand why the gland of the nictating membrane sometimes protrudes from its original position but it is believed to be a result of a weakness in the connective tissue responsible for holding the gland in the correct position.

This condition can happen to any breed of dog but is seen most commonly in certain breeds, including the American cocker spaniel, English bulldog, Lhasa apso, and the Pekinese, Collins said.

Pet owners who spot a red swollen mass in the inner corner of their pets eye, large or small, should bring it to their veterinarians attention promptly. In addition to causing irritation to the dog, this condition can have lasting consequences when left untreated.

Without correction, chronic prolapse can lead to conjunctivitis (pink eye) and ocular discharge (liquid coming from the eye), Collins said. It has also been shown that with correction, dogs are less likely to develop low tear production later in life.

Low tear production can result in multiple problems if left untreated. In addition to pain and decreased vision, corneal ulceration may also develop, which can become infected and result in a ruptured eye. This condition responds well to tear stimulant therapy in most cases, but lifelong medication is usually required.

Your veterinarian will be able to confirm whether your pet has cherry eye and can develop a treatment plan that works best to resolve cherry eye and reduce the potential for ocular issues as your dog ages.

Initial therapy may consist of topical anti-inflammatory therapy if local inflammation may be contributing to prolapse of the gland, he said. If a short course of medical therapy does not work or re-prolapse develops, surgical repositioning is indicated. There are numerous surgical techniques to reposition the gland with overall high success rates.

If surgical treatment is required, Collins stresses that this treatment will benefit your pet in both the short- and long-term.

Surgical repositioning is very important if initial medical therapy fails, as the gland is responsible for about 30-50% of the aqueous tear production in the dog, he said. We commonly see low tear production in the same breeds that develop a prolapsed gland of the nictitans. It has been shown that dogs with surgical repositioning of the gland have a lower chance of developing low tear production later on in life compared to those where the gland has been excised or remains chronically prolapsed.

Unfortunately, there are no known preventative measures to protect against cherry eye, Collins says. This condition can develop in both eyes, usually before the age of 2. The best way pet owners can protect their furry friend is to remain vigilant in monitoring their pets health and to bring concerns to their veterinarian promptly in case an issue does arise.

Pet Talk is a service of the College of Veterinary Medicine & Biomedical Sciences, Texas A&M University. Stories can be viewed on the web at vetmed.tamu.edu/news/pet-talk. Suggestions for future topics may be directed to editor@cvm.tamu.edu.

Continued here:
PET TALK: Seeing the signs: What to know about cherry eye in dogs - Houston Chronicle

Read More...

Pet talk: Seeing the signs: What to know about cherry eye In dogs – Marshall News Messenger

December 8th, 2020 8:00 pm

BRYAN-COLLEGE STATION Spotting a red bump in the corner of a pets eye is a concerning but not uncommon experience for many dog owners. Colloquially called cherry eye, this bump may be a prolapsed gland of the nictitans, also known as the third eyelid.

Dr. Sean Collins, a clinical assistant professor at the Texas A&M University College of Veterinary Medicine & Biomedical Sciences, says that ophthalmologists dont entirely understand why the gland of the nictating membrane sometimes protrudes from its original position, but it is believed to be a result of a weakness in the connective tissue responsible for holding the gland in the correct position.

This condition can happen to any breed of dog but is seen most commonly in certain breeds, including the American cocker spaniel, English bulldog, Lhasa apso, and the Pekinese, Collins said.

Pet owners who spot a red swollen mass in the inner corner of their pets eye, large or small, should bring it to their veterinarians attention promptly. In addition to causing irritation to the dog, this condition can have lasting consequences when left untreated.

Without correction, chronic prolapse can lead to conjunctivitis (pink eye) and ocular discharge (liquid coming from the eye), Collins said. It has also been shown that with correction, dogs are less likely to develop low tear production later in life.

Low tear production can result in multiple problems if left untreated. In addition to pain and decreased vision, corneal ulceration may also develop, which can become infected and result in a ruptured eye. This condition responds well to tear stimulant therapy in most cases, but lifelong medication is usually required.

Your veterinarian will be able to confirm whether your pet has cherry eye and can develop a treatment plan that works best to resolve the issue and reduce the potential for ocular issues as your dog ages.

Initial therapy may consist of topical anti-inflammatory therapy if local inflammation may be contributing to prolapse of the gland, he said. If a short course of medical therapy does not work or re-prolapse develops, surgical repositioning is indicated. There are numerous surgical techniques to reposition the gland with overall high success rates.

If surgical treatment is required, Collins stresses that this treatment will benefit your pet in both the short- and long-term.

Surgical repositioning is very important if initial medical therapy fails, as the gland is responsible for about 30-50% of the aqueous tear production in the dog, he said. We commonly see low tear production in the same breeds that develop a prolapsed gland of the nictitans. It has been shown that dogs with surgical repositioning of the gland have a lower chance of developing low tear production later on in life compared to those where the gland has been excised or remains chronically prolapsed.

Unfortunately, there are no known preventative measures to protect against cherry eye, Collins said. This condition can develop in both eyes, usually before the age of two. The best way owners can protect their furry friend is to remain vigilant in monitoring their pets health and to bring concerns to their veterinarian promptly in case an issue does arise.

Pet Talk is a service of the College of Veterinary Medicine & Biomedical Sciences, Texas A&M University. Stories can be found on the Pet Talk website. Suggestions for future topics may be directed to editor@cvm.tamu.edu.

Read the original:
Pet talk: Seeing the signs: What to know about cherry eye In dogs - Marshall News Messenger

Read More...

Global Veterinary Medicine Market to Get Expansion admist COVID 19, Scope With Advanced Technologies Top Key Players and Forecast 2020-2027 – The…

December 8th, 2020 8:00 pm

Global Veterinary Medicine MarketIndustry Trends and Forecast to 2028 New Research Report Added to Databridgemarketresearch.com database. The report width Of pages : 350 Figures: 60 And Tables: 220 in it. Global Veterinary Medicine Market describes complete industry Outlook with in-depth analysis. This report also Includes the complete analysis of each segment in terms of opportunity, market attractiveness index and growth rate, top players and new comers in industry, competitive landscape, sales, price, revenue, gross margin, market share, market risks, opportunities, market barriers, and challenges.key statistics on the market status. which give the clear idea about the product differentiation and an understanding of competitive landscape Globally.

Global Veterinary Medicine Market Research report comprises of a brief summary on the trends and tendency that may help the key market players functioning in the industry to understand the market and strategize for his or her Organisation expansion for this reason. This statistical surveying report examines the entire market size, market share, key segments, growth, key drivers, CAGR, historic data, present market trends And End User Demand, environment, technological innovation, upcoming technologies and the technical progress in the industry.

Veterinary medicine marketis expected to reach a market value of USD 45.6 billion by 2027 whilegrowat a potential rate of 7.15% in the forecast period of 2020 to 2027. Growing number of pet adoption will help in the growth of theveterinarymedicine market.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-veterinary-medicine-market

Major players

The major players covered in the veterinary medicine market report are Merck & Co., Inc., Ceva, Vetoquinol S.A., Zoetis, BoehringerIngelheim International GmbH, Bayer AG, Elanco.,Nutreco N.V.,Virbac., Kindred Biosciences, Inc., BiogenesisBago, infocusrx., NEOGEN CORPORATION, Hester Biosciences Limited., Cargill, Incorporated., ADM Animal Nutrition,among other domestic and global players.

Patient Epidemiology Analysis

Veterinary medicine market also provides you with detailed Customization Available: Global Veterinary Medicine Market

market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Increasing prevalence of veterinary professionals, growing demand of pet insurance, increasing initiatives by the government as well as private regarding animal health, rising consumption of meat and mandatory vaccinations, growinglivestockpopulation as well as pet ownership rates will likely to enhance the growth of the veterinary medicine market in the forecast period of 2020-2027. On the other hand, increasing research and development for procedural advancement will further boost various opportunities that will lead to the growth of the veterinary medicine market in the above mentioned forecast period.

Rising number of counterfeit drugs, rising occurrences of various infections will likely to hinder the growth of the veterinary medicine market in the mentioned forecast period.

This veterinary medicine market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the veterinary medicine market scenario contactData Bridge Market Researchfor anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-veterinary-medicine-market

Global Veterinary Medicine Market Scope and Market Size

Veterinary medicine market is segmented on the basis ofproduct, animal type, mode of delivery and end-use. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Veterinary Medicine Market Country Level Analysis

Veterinary medicine market is analysed and market size information is provided by country by product, animal type, mode of delivery and end use as referenced above.

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-veterinary-medicine-market

North America dominates the veterinary medicine market due to prevalence of favourable government policies along with rising initiatives to improve animal health while the Asia-Pacific region is expected to grow at the highest growth rate in the forecast period of 2020 to 2027 because of expansion of manufacturing facilities and vaccination for livestock animals.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @Corporatesales@databridgemarketresearch.com

Read the rest here:
Global Veterinary Medicine Market to Get Expansion admist COVID 19, Scope With Advanced Technologies Top Key Players and Forecast 2020-2027 - The...

Read More...

Endemic Corruption Is Reason Behind Alarming Wildlife Trafficking From Nigeria – Voice of America

December 8th, 2020 8:00 pm

ABUJA - Corruption has made Nigeria the biggest smuggler of ivory and pangolin scales from central and West Africa to Asia, according to a report by the Environmental Investigation Agency. The London-based group says in the past five years, Nigeria has been implicated in global seizures equating to 4,400 elephants and hundreds of thousands of endangered pangolins.

Aaron Olamilekan, a Nigerian wildlife advocate, spoke as he held a dead pangolin he bought from a group of local hunters arriving from a hunt on the outskirts of Abuja.

"They tell me why most of them hunt. It's based on poverty; there's no good job for them, there's no government support for them. So, they have no choice than to go into the wild," Olamilekan said.

The hunters sell the animals in exchange for cash.

But Olamilekan sometimes intercepts them, negotiates and rescues endangered species.

Animals returned to wild

He runs a sanctuary where he says animals can be resuscitated and nurtured before they're released into the wild.

"The ecosystem is being tampered with because all these animals have a role to play in our environment, so killing them will cause a future disaster," Olamilekan said.

Illegal hunting for trade is the major reason that endangered species such as elephants and pangolins are in constant decline.

Since 2015, Nigeria has been the main exit point for pangolin scales and elephant ivory from the continent to many parts of Asia, where they are prized for decorative purposes or their alleged but unproven medicinal uses.

Smugglers take ivory, scales

A recent report by the Environmental Investigation Agency (EIA) shows more than 30 tons of ivory and 167 tons of pangolin scales have been smuggled through the country in five years.

The EIA blames corruption by Nigerian border or port officials for the illegal trade. Shruti Suresh is a senior wildlife campaigner at EIA.

"Corruption which exists within certain public sectors is helping organized crime to thrive and traffic ivory, pangolin, and several other species." Suresh said. "We need political will at the highest level of government to prioritize this issue."

Nigeria is a member of several international conventions protecting endangered wildlife, including the Convention on International Trade of Endangered Species (CITES).

Laws rarely enforced

Nigerian authorities continue to pledge their commitment toward protecting wildlife even though laws meant to safeguard endangered species are rarely enforced.

The EIA wants Nigerian authorities to take stricter measures against poachers and smugglers, noting that uncontrolled trade during this period of the coronavirus pandemic could be potentially dangerous.

For the moment, wildlife advocate Olamilekan will be saving as many endangered animals as possible.

More here:
Endemic Corruption Is Reason Behind Alarming Wildlife Trafficking From Nigeria - Voice of America

Read More...

Vivos Inc to Present at The 13th Annual LD Micro Main Event Conference December 15, 2020 11:00 AM Eastern Standard Time – GlobeNewswire

December 8th, 2020 8:00 pm

Richland WA, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL``), Vivos Inc (RDGL), a company that has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals and in humans, today announced that it will be presenting at the 13th annual LD Micro Main Event investor conference on Tuesday, December 15, 2020 at 8:00 AM PST / 11:00 AM EST. Mike Korenko, CEO of Vivos Inc., will be presenting to a live virtual audience.

Register here:ve.mysequire.com/

The Main Event will feature a new and unique format, with companies presenting for 10 minutes, followed by 10 minutes of Q&A by a panel of investors and analysts.

"The time has finally come to do something different in the virtual conference world. Lets see if we can pull off something that can be enjoyed by both executives and investors alike, stated Chris Lahiji, Founder of LD, now a wholly owned subsidiary of SRAX, Inc.

The Main Event will take place on December 14th and 15th, exclusively on the Sequire Virtual Events platform.

View Vivos Incs profile here http://ldmicro.com/profile/RDGL

View Vivos Incs site here: http://www.RadioGel.com

About Vivos Inc. (OTCQB: RDGL)

Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (Isopet) and in humans (Radiogel). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the companys proprietary hydrogel technology. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.

Radiogel is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

Radiogel also has a short half-life delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to family members.

The Isopet Solutions division used university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at the Washington State University was completed in 2018 and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019.

In 2018 the Company obtained confirmation from the FDA Center for Veterinary Medicine that Isopet is classified as a medical device according to its intended use and means by which it achieves its intended purpose. The FDA also reviewed the product labeling which included canine and feline sarcomas as the initial indications for use. The FDA does not require pre-market approval for veterinary devices so no additional approval is required. Following the demonstration phase, Vivos is able to generate revenue through the sale of Isopet to University animal hospitals and private veterinary clinics.

Isopet for treating animals uses the same technology as RadioGel for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

CONTACT:

Vivos Inc.Michael K. Korenko, Sc.D.President & CEOMKorenko@RadioGel.com

About LD Micro/SEQUIRELD Micro began in 2006 with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. For more information, please visitldmicro.com.

The upcoming Main Event will be highlighting a new format that will benefit both executives and the investors tuning in from all over the globe.

In September 2020, LD Micro, Inc. was acquired by SRAX, Inc., a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform,Sequire, companies can track their investors behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visitsrax.comandmysequire.com.

ContactsInvestor Relations Contact:Brett MaasHayden IR, LLCbrett@haydenir.com646-536-7331

See the original post here:
Vivos Inc to Present at The 13th Annual LD Micro Main Event Conference December 15, 2020 11:00 AM Eastern Standard Time - GlobeNewswire

Read More...

Drake is selling a candle that smells like … Drake, and more of this week’s weirdest news – Napa Valley Register

December 8th, 2020 8:00 pm

Astronauts are harvesting fresh radishes grown in space, a delicious prospect that also could help seed food production efforts for longer-term missions to the moon and Mars.

The Advanced Plant Habitat cultivates radishes, a plant that is nutritious, edible and has a short cultivation time.

On Monday, NASA flight engineer Kate Rubins pulled out 20 radish plants grown in the space station's Advanced Plant Habitat, wrapping them in foil for cold storage until they can make the voyage back to Earth next year.

Radishes are the latest type of fresh produce to be successfully grown and harvested in zero gravity, joining "Outredgeous" red romaine lettuce, green lettuce, Chinese cabbage, lentils and mustard, according to a NASA fact sheet.

"I've worked on APH since the beginning, and each new crop that we're able to grow brings me great joy because what we learn from them will help NASA send astronauts to Mars and bring them back safely," said Nicole Dufour, the Advanced Plant Habitat program manager at NASA's Kennedy Space Center, in a news release.

Food for future space missions

Back on the ground, scientists at the Kennedy Space Center in Florida are growing radishes in a control group set for harvest on December 15. The researchers will compare the space-grown radishes to the veggies grown on Earth, checking on how space produce measures up on providing the minerals and nutrients astronauts need as they prepare for longer trips.

Meanwhile, astronauts will repeat the radish experiment in the heavens, planting and harvesting another round of radish crop to give scientists more data to draw from.

With their short cultivation time, radishes present potential advantages as a food source for future astronauts embarking on deep space missions in years to come. The radishes grow quickly, and they can reach full maturity in 27 days.

The root vegetables also don't require much maintenance from the crew as they grow.

astronaut and flight engineer Kate Rubins checks out radish plants growing on the space station as part of an experiment to evaluate nutrition and taste of the plants.

"Radishes provide great researchpossibilities by virtue of their sensitive bulb formation," said Karl Hasenstein, a professor of biology at the University of Louisiana and the principal investigator on the project, in a news release.

Researchers will analyze the effects of carbon dioxide on the radishes as well as how the vegetables acquire and distribute minerals, according to Hasenstein, who has run plant experiments with NASA since 1995.

Astronauts have grown 15 different types of plants on the station, including eight different types of leafy greens. And NASA has already tested more than 100 crops on Earth, identifying which candidates to try out next in space.

"Growing a range of crops helps us determine which plants thrive in microgravity and offer the best variety and nutritional balance for astronauts on long-duration missions," Dufour said.

Years of research with space crops

The latest experiments build upon ongoing research growing and harvesting plants in space.

Researchers at NASA began experiments using its Vegetable Production Systems growth chambers back in 2014 shortly after they were delivered to the space station.

Some of the early experiments with red romaine lettuce resulted in a paper, published this March in the journal Frontiers in Plant Science, showing that space lettuce was safe to eat.

In August 2015, NASA shared a video that features American astronauts Dr. Kjell Lindgren and Scott Kelly floating aboard the station, saying "Cheers" and eating the space-grown treat.

"Tastes good," Kelly said.

Getting space agriculture right matters because the nutrients in the prepackaged food that astronauts currently eat in space degrade over a period of time, NASA said.

Getting humans to Mars and back safely over a two- or three-year mission requires growing food along the way. That not only gives astronauts more of a vibrant supply of fresh nutrients on the voyage; it also serves an emotional need as they tend to crops that are both a figurative and literal taste of home, according to the agency.

The NASA Artemis program aims to land the first woman and next man on the moon in 2024, and to establish a sustained presence on the moon by 2028. From there, the agency will be poised to begin staging its next big leap, to Mars.

But before we make it to the red planet, we've first got to make a tasty green space salad.

CNN's Ashley Strickland contributed to this story.

Continued here:
Drake is selling a candle that smells like ... Drake, and more of this week's weirdest news - Napa Valley Register

Read More...

Insights on the Global Stem Cell Therapy Market 2020-2024: COVID-19 Analysis, Drivers, Restraints, Opportunities, and Threats – Technavio – Business…

December 8th, 2020 7:58 pm

LONDON--(BUSINESS WIRE)--The stem cell therapy market is expected to grow by USD 588.22 mn, progressing at a CAGR of almost 7% during the forecast period.

Click & Get Free Sample Report in Minutes

The increase in awareness of stem cell therapy is one of the major factors propelling market growth. However, factors such as the high cost of clinical trials will hamper the market growth.

More details: https://www.technavio.com/report/stem-cell-therapy-market-industry-analysis

Stem Cell Therapy Market: Type Landscape

Based on the type, the allogeneic transplants segment is expected to witness lucrative growth during the forecast period.

Stem Cell Therapy Market: Geographic Landscape

By geography, North America is going to have a lucrative growth during the forecast period. About 51% of the markets overall growth is expected to originate from North America. The US and Canada are the key markets for the stem cell therapy market in North America.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Related Reports on Health Care Include:

Companies Covered:

What our reports offer:

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Key Topics Covered:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Type

Customer landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Read the original post:
Insights on the Global Stem Cell Therapy Market 2020-2024: COVID-19 Analysis, Drivers, Restraints, Opportunities, and Threats - Technavio - Business...

Read More...

Page 305«..1020..304305306307..310320..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick